Hexapeptide-9
Also known as: Collaxyl, Collaxyl IS, Collaxyl ng, Gly-Pro-Gln-Gly-Pro-Gln
Key Facts: Hexapeptide-9
- Category
- Skin & Hair
- FDA Status
- Not FDA Approved
- Clinical Status
- Cosmetic ingredient used in anti-wrinkle and firming products. Not an FDA-approved drug: cosmetics and their ingredients (except color additives) do not need FDA approval before sale, and hexapeptide-9 has never been through drug trials. Evidence is small and largely industry-linked.
- Banned in Sport (WADA)
- Not on the WADA Prohibited List (2026). It is a topical cosmetic ingredient, and skincare use is not a known anti-doping issue.
- Administration
- Topical (serums, creams)
- Typical Dose
- Low single-digit percent of the ingredient in a finished product
- Frequency
- Once or twice daily
- Duration
- 4-8 weeks in studies; ongoing use to maintain any effect
How does Hexapeptide-9 work?
Hexapeptide-9 is Gly-Pro-Gln-Gly-Pro-Gln, a repeat taken from collagen sequences. Ashland says the sequence is found in collagen IV and XVII and works as a matrikine, a matrix fragment that signals cells to make more matrix proteins. The claimed targets are the dermal-epidermal junction (collagen IV, laminin-5, integrins) and collagen production. The original patent describes it as designed to improve cell adhesion and possibly support matrix production. One weakness is stability: the linear peptide is easily broken down by collagen-digesting enzymes, which is why a Chinese group built a ring-shaped (cyclized) version to make it last longer in skin.
What does the research show?
The oldest human data is a 2004 study from Vincience, the lab behind Collaxyl: a double-blind, placebo-controlled test of a gel containing 3% of a 'collagen-like hexapeptide' plus a 1% booster ingredient, applied around the eyes of 20 women for four weeks. It reported fewer and shallower wrinkles on skin replicas, but the booster and the small size mean it cannot prove the peptide alone did the work. Supplier material cites other 28-day studies in about 20 volunteers that we could not trace to journals. The newest and best-designed study is a 2025 randomized, double-blind trial in the Journal of Cosmetic Dermatology (96 adults aged 30-55 in China) comparing a cyclized hexapeptide-9 serum at 0.002% with 0.002% retinol and a vehicle for 56 days. The cyclized peptide beat both on wrinkle, elasticity and hydration measures, with no treatment-related side effects. Two caveats: it tested a modified molecule, not the Collaxyl peptide in most products, and several authors are affiliated with cosmetic companies. Bottom line: the concept has some support, the cyclic version looks promising, but regular hexapeptide-9 in a store-bought cream rests on thin evidence.
What doses have been studied?
Typical Dosingⓘ
Community experience
Low single-digit percent of the ingredient in a finished product
Published studies used 0.002% (cyclic form) up to 3% of a peptide gel
Once or twice daily
These are cosmetic formulation levels, not personal doses. Product labels rarely state the actual peptide content. There is no injectable or oral use with human data.
Research Dosingⓘ
Scientific studies
Cosmetic formulation levels from published studies. Supplier use levels for Collaxyl are not publicly confirmed. Not a dosing recommendation.
Doses from Studies
3% hexapeptide gel twice daily for 4 weeks (20 women, with 1% booster)
Research Literature (developer-run) - Bauza et al. 2004, Int J Tissue React ↗
0.002% cyclized hexapeptide-9 twice daily for 56 days
Research Literature (randomized trial) - Chang et al. 2025, J Cosmet Dermatol ↗
Duration
4-8 weeks in studies; ongoing use to maintain any effect
Administration
Topical (serums, creams)
When and how is Hexapeptide-9 taken?
Best Time to Take
Morning and/or evening, on clean skin
Once or twice daily, ongoing
Food Recommendation
With or without food
Why This Timing?
Studies used twice-daily application. Timing is less important than steady use; use sunscreen in the day.
What are the side effects of Hexapeptide-9?
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well tolerated
- ●No treatment-related adverse events reported in the 2025 trial
- ●Mild irritation or redness possible, often from the overall formula
- ●Contact allergy possible, as with any skincare ingredient
References
- https://pubmed.ncbi.nlm.nih.gov/15648443/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12207714/
- https://ashland.com/industries/personal-and-home-care/skin-and-sun-care/collaxyl-ng-biofunctional
- https://www.evigrade.com/en/ingredients/hexapeptide-9
- https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
Research This Peptide Further
Frequently Asked Questions
What does Hexapeptide-9 do?
Hexapeptide-9 is a collagen-inspired signaling peptide sold as Collaxyl (originally from Vincience, now Ashland) for anti-wrinkle and firming skincare. The idea is that a small repeat of a collagen sequence nudges skin cells to rebuild the junction between the outer and inner skin. It is a cosmetic ingredient, and the evidence for the original peptide is mostly old, small and company-run, although a 2025 trial on a modified cyclic version is more interesting.
How does Hexapeptide-9 work?
Hexapeptide-9 is Gly-Pro-Gln-Gly-Pro-Gln, a repeat taken from collagen sequences. Ashland says the sequence is found in collagen IV and XVII and works as a matrikine, a matrix fragment that signals cells to make more matrix proteins. The claimed targets are the dermal-epidermal junction (collagen IV, laminin-5, integrins) and collagen production. The original patent describes it as designed to improve cell adhesion and possibly support matrix production. One weakness is stability: the linear peptide is easily broken down by collagen-digesting enzymes, which is why a Chinese group built a ring-shaped (cyclized) version to make it last longer in skin.
Is Hexapeptide-9 FDA approved?
No, Hexapeptide-9 is not currently FDA approved. Current status: Cosmetic ingredient used in anti-wrinkle and firming products. Not an FDA-approved drug: cosmetics and their ingredients (except color additives) do not need FDA approval before sale, and hexapeptide-9 has never been through drug trials. Evidence is small and largely industry-linked.
Is Hexapeptide-9 banned in sport?
Not on the WADA Prohibited List (2026). It is a topical cosmetic ingredient, and skincare use is not a known anti-doping issue.
What are the side effects of Hexapeptide-9?
Reported side effects include: Generally well tolerated, No treatment-related adverse events reported in the 2025 trial, Mild irritation or redness possible, often from the overall formula, Contact allergy possible, as with any skincare ingredient. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Hexapeptide-9?
Community-reported common dose: Low single-digit percent of the ingredient in a finished product (Once or twice daily). Range: Published studies used 0.002% (cyclic form) up to 3% of a peptide gel. Administration: Topical (serums, creams). Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Hexapeptide-9 or used in similar applications.
GHK-Cu
Clinical TrialsGHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.
Skin & HairMatrixyl
ResearchMatrixyl is the trade name (Sederma) for palmitoyl pentapeptide-4, also written Pal-KTTKS, a collagen-fragment peptide attached to a fatty acid so it can cross skin. Unlike Botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. It is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof.
Skin & HairMatrixyl 3000
ResearchMatrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.
Skin & HairCopper Peptide AHK-Cu
ResearchAHK-Cu is a synthetic copper-bound tripeptide, alanine-histidine-lysine complexed with a copper ion, engineered mainly for hair and scalp products. It is the lesser-known sibling of the naturally occurring GHK-Cu copper peptide, designed in the lab specifically to push hair follicles to keep growing. It is a cosmetic and research ingredient, not an approved hair-loss drug, and its evidence is essentially limited to one notable lab study.
Skin & HairPalmitoyl Tripeptide-38
ResearchPalmitoyl tripeptide-38 is the active in Sederma's Matrixyl synthe'6, a newer member of the Matrixyl family launched around 2011. It is a three-amino-acid fragment with a fatty acid tail, sold as a wrinkle 'filler from the inside' for forehead lines and crow's feet. It is a cosmetic ingredient, not a drug, and the honest picture is simple: the efficacy claims come almost entirely from the company that makes it.
Skin & HairAcetyl Tetrapeptide-5
ResearchAcetyl tetrapeptide-5 is a short synthetic peptide sold by Lipotec (now Lubrizol) as Eyeseryl, made for eye creams that target under-eye puffiness. The pitch is that it reduces fluid leaking into the tissue under the eyes. It is a cosmetic ingredient, and nearly all of the human data comes from the company that sells it.
Skin & HairWant updates on Hexapeptide-9 research?
Get an email when we add new research here, when it is back in stock, or when the price drops.